Dizal Pharmaceutical(SH:688192) Zheng Quan Zhi Xing·2025-08-22 09:22Fundraising Overview - The company raised a total of RMB 1,986,567,781.57 from its initial public offering, verified by PwC [1] - In 2025, the company raised RMB 1,795,886,744.00 from a targeted issuance, with a net amount of RMB 1,773,446,130.53 after deducting issuance costs [2] Fund Utilization - As of June 30, 2025, the company has utilized RMB 1,641,979,531.17 of the raised funds, with RMB 4,761,963.69 remaining in the special account [3][4] - The company has engaged in cash management with temporarily idle funds amounting to RMB 415,000,000.00 [3][11] Fund Management - The company has established a management system for the raised funds, adhering to relevant laws and regulations, and has implemented a special account management approach [5] - A tripartite supervision agreement was signed with the sponsoring institution and banks to ensure proper management of the raised funds [6][7] Cash Management - The company has approved the use of idle funds for cash management, investing in safe and liquid financial products, with a maximum limit of RMB 50,000,000.00 [10] - As of June 30, 2025, the company has RMB 390,000,000.00 in cash management from the targeted issuance [14] Fund Replacement and Reallocation - The company has replaced RMB 136,542,332.57 of the initial public offering funds and RMB 2,671,312.36 from the targeted issuance with self-raised funds for project investments [16] - There were no instances of using excess funds for permanent working capital or repaying bank loans during the reporting period [15] Project Investment Status - The company has not changed the use of funds for investment projects during the reporting period and has complied with all regulations regarding fund usage [19]